Mayo Clinic Rochester Minnesota, Rochester, USA.
Leuk Lymphoma. 2022 Sep;63(9):2033-2040. doi: 10.1080/10428194.2022.2068008. Epub 2022 May 9.
Smoldering multiple myeloma has been recognized for over 40 years and represents a pre-symptomatic phase of the 2nd most common hematologic malignancy. 1/3 of patients will remain asymptomatic at 10 years. There is an identifiable subset of patients that will develop CRAB within 2 years of recognition and these patients are considered for therapeutic intervention before the development of potentially irreversible complications. Obstacles to widespread implementation of therapeutic guidelines are limited by the variable definitions associated with this high-risk group as well as the poor concordance between classification schemes. Analysis of clinical trial outcomes as well as uniform eligibility helps determine whether a given patient should be considered for therapeutic intervention outside of a clinical trial.
冒烟型多发性骨髓瘤被认识已经超过 40 年，代表了第 2 大常见血液恶性肿瘤的一个亚临床前期。1/3 的患者在 10 年内仍无症状。有一个可识别的亚组患者在被识别后的 2 年内会发展为 CRAB，这些患者在可能出现不可逆转的并发症之前被考虑进行治疗干预。治疗指南的广泛实施受到与该高危人群相关的可变定义以及分类方案之间的一致性较差的限制。临床试验结果的分析以及统一的资格标准有助于确定是否应考虑在临床试验之外对特定患者进行治疗干预。
